Accessibility Menu
Medical Developments International logo

Medical Developments International(ASX) MVP

Market CapA$54.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+28%
5 Year-89%
1 Year-37%
1 Month+12%
A$0.46
+0.00%
+0.00Today
Medical Developments International last closing stock price
MetricPriceDate
Last closeAUD 0.462026-08-13
Medical Developments International stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8%AUD 0.502026-08-06
1 month+12.2%AUD 0.412026-07-14
3 month+6.98%AUD 0.432026-05-15
Year to date-17.12%AUD 0.562025-12-31
1 year-36.99%AUD 0.732025-08-13
3 year-56.19%AUD 1.052023-08-14
5 year-88.7%AUD 4.072021-08-13
Since inception+27.64%AUD 0.382003-12-15

Medical Developments International Financials at a Glance

Market Cap

A$54.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$78.69M

Net Income (TTM)

-A$30.18M

EPS (TTM)

-A$0.00

P/E Ratio

-123.08

Dividend

A$0.00

Beta (Volatility)

0.17 (Low)

Price

A$0.46

Volume

1,400

Open

A$0.46

Previous Close

A$0.46

Daily Range

A$0.46 - A$0.46

52-Week Range

A$0.37 - A$0.77

Estimated Earnings Date

Aug 20, 2026

MVP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Medical Developments International

Medical Developments International Limited specializes in the development and provision of essential emergency medical solutions, serving global markets including Australia, Europe, and the United States. The company operates primarily in two segments: Pain Management and Respiratory care, with a focus on innovative products like Penthrox for rapid pain relief.

Products and Services
  • Penthrox, a fast-acting analgesic for acute pain relief
  • Respiratory care equipment for asthma and COPD patients
  • Diverse medical devices including CPR face shields and oxygen therapy kits
Growth Outlook
  • Revenue increased to AUD 21.57 million in the latest quarter
  • Gross profit margin improved to 31.1% in Q2 2025
  • Strong cash position with AUD 16.88 million in cash and equivalents
Financial Highlights
  • Trailing twelve months revenue of AUD 69.5 million
  • Operating income margin at -0.0017 in Q2 2025
  • Current ratio of 6.07 indicates strong liquidity
Medical Developments International Limited is positioned in the healthcare sector, focusing on innovative solutions that address critical medical needs. The company's flagship product, Penthrox, has gained recognition for its effectiveness in emergency situations, contributing to its growth in the Pain Management segment. The respiratory care segment also plays a vital role, catering to patients with chronic conditions. Recent financial performance shows a notable increase in revenue, reflecting the company's ability to capture market demand. The improvement in gross profit margin indicates operational efficiency, while a robust cash position supports future growth initiatives. With a strong liquidity ratio, Medical Developments International Limited is well-equipped to navigate the evolving healthcare landscape.
AI Generated • Jul 26, 2026

Industry

Pharmaceuticals

CEO

Brent MacGregor, MBA

Headquarters

Scoresby, VIC 3179, AU

MVP Financials

Key Financial Metrics (TTM)

Gross Margin

52.71%

Operating Margin

0.83%

Net Income Margin

-1.07%

Return on Equity

-0.79%

Return on Capital

5.38%

Return on Assets

-0.69%

Earnings Yield

-0.81%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$54.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

112.66M

Volume

1.40K

Avg. Volume

180.08K

Financials (TTM)

Gross Profit

A$39.09M

Operating Income

-A$831.00K

EBITDA

-A$13.56M

Operating Cash Flow

-A$4.09M

Capital Expenditure

-A$2.22M

Free Cash Flow

-A$6.31M

Cash & ST Invst.

A$16.88M

Total Debt

A$3.34M

Medical Developments International Performance Analysis

Medical Developments International annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 21,943,000N/A
20232023-06-30AUD 32,337,00047.4%
20242024-06-30AUD 33,149,0002.5%
20252025-06-30AUD 39,056,00017.8%
Medical Developments International sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3019.8%
Q22024-12-3110.6%
Q42025-06-30-4.6%
Q22025-12-3113.1%
Medical Developments International annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.17N/A
20232023-06-30AUD -0.06-61.2%
20242024-06-30AUD -0.46614.0%
20252025-06-30AUD 0.00N/A
Medical Developments International sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-183.3%
Q22024-12-31100.8%
Q42025-06-30-170.4%
Q22025-12-31-5.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$21.57M

+43.0%

Gross Profit

A$6.72M

+223.2%

Gross Margin

31.13%

N/A

Market Cap

A$54.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$795.23K

N/A

Employees

68

N/A

Net Income

-A$226.00K

+97.9%

EBITDA

A$1.33M

+111.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$16.88M

+7.5%

Total Debt

A$3.34M

+37.5%

Accounts Receivable

A$7.48M

+54.5%

Inventory

A$8.50M

-10.6%

Long Term Debt

A$3.01M

+45.9%

Short Term Debt

A$330.00K

-9.6%

Return on Assets

-0.69%

N/A

Return on Invested Capital

0.58%

N/A

Free Cash Flow

A$62.00K

+100.8%

Operating Cash Flow

A$284.00K

+104.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SHG.AXSingular Health Group Ltd
A$0.19+0.00%
M7T.AXMach7 Technologies Limited
A$0.28-1.79%
CYC.AXCyclopharm Limited
A$0.52+0.00%
NXS.AXNext Science Limited
A$0.15+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About MVP

What is the current price of Medical Developments International?

Medical Developments International is trading at A$0.46 per share.

What is the 52-week range for Medical Developments International?

Over the past 52 weeks, Medical Developments International has traded between A$0.37 and A$0.77.

How much debt does Medical Developments International have?

As of the most recent reporting period, Medical Developments International reported total debt of A$1.99M.

How much cash does Medical Developments International have on hand?

Medical Developments International reported A$17.84M in cash and cash equivalents in its most recent financial results.

What is Medical Developments International’s dividend yield?

Medical Developments International does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.